FierceBiotech Radio on Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand

FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, and Merck KGaA's big push to distance itself from that other Merck.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to